Trellis Bioscience discovers and develops novel human antibody therapeutics as treatment for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other characteristics. The company has built a pipeline of monoclonal antibodies focused on infectious disease, with the most advanced being an IND candidate for treatment of Respiratory Syncytial Virus, licensed to Medimmune.
Latest News
December 29, 2011
Trellis presents new data on Influenza and CMV programs at IBC conference in San Diego, Dec 3-6, 2011. 
August 31, 2011
Trellis Bioscience, LLC receives two separate SBIR grants from NIAID
May 31, 2011
Trellis Bioscience, LLC announced today issuance of US patent 7,939,344
The Trellis Blog
January 02, 2012
Trellis commences partnering its CMV and Flu mAb programs at the J.P. Morgan Conference in San Francisco, January 9-12, 2012.
September 06, 2011
Dec 4-8, 2011 San Diego IBC Antibody Therapeutics 22nd Annual Meeting, San Diego, CA
July 20, 2011
Past Presentations: American Society of Virology (ASV) Minneapolis, MN July, 2011